41975-14-8 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
4-(5-Chlorothiazolo[5,4-d]pyriMidin-7-yl)Morpholine is utilized as a potential drug candidate for its unique structural features and biological activities. Its specific interactions and mechanisms of action are under exploration, with the aim of identifying its potential in treating a range of medical conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(5-Chlorothiazolo[5,4-d]pyriMidin-7-yl)Morpholine is employed as a compound of interest for the design and synthesis of new pharmaceutical agents. Its complex structure and the presence of a chloro group may offer novel avenues for the development of drugs with improved efficacy and selectivity.
Used in Chemical Synthesis:
4-(5-Chlorothiazolo[5,4-d]pyriMidin-7-yl)Morpholine is used as a key intermediate in the synthesis of other complex organic molecules. Its unique structural elements, including the morpholine and thiazole-pyrimidine rings, make it a valuable building block for creating new chemical entities with potential applications in various industries.
Used in Biochemical Studies:
In biochemical research, 4-(5-Chlorothiazolo[5,4-d]pyriMidin-7-yl)Morpholine is used to study its interactions with biological targets, such as enzymes, receptors, or other proteins. Understanding these interactions can provide insights into its potential therapeutic effects and help in the optimization of its structure for specific applications.
Check Digit Verification of cas no
The CAS Registry Mumber 41975-14-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,1,9,7 and 5 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 41975-14:
(7*4)+(6*1)+(5*9)+(4*7)+(3*5)+(2*1)+(1*4)=128
128 % 10 = 8
So 41975-14-8 is a valid CAS Registry Number.
41975-14-8Relevant articles and documents
Potent and highly selective benzimidazole inhibitors of PI3-kinase delta
Murray, Jeremy M.,Sweeney, Zachary K.,Chan, Bryan K.,Balazs, Mercedesz,Bradley, Erin,Castanedo, Georgette,Chabot, Christine,Chantry, David,Flagella, Michael,Goldstein, David M.,Kondru, Rama,Lesnick, John,Li, Jun,Lucas, Matthew C.,Nonomiya, Jim,Pang, Jodie,Price, Stephen,Salphati, Laurent,Safina, Brian,Savy, Pascal P. A.,Seward, Eileen M.,Ultsch, Mark,Sutherlin, Daniel P.
, p. 7686 - 7695 (2012)
Inhibition of PI3Kδ is considered to be an attractive mechanism for the treatment of inflammatory diseases and leukocyte malignancies. Using a structure-based design approach, we have identified a series of potent and selective benzimidazole-based inhibitors of PI3Kδ. These inhibitors do not occupy the selectivity pocket between Trp760 and Met752 that is induced by other families of PI3Kδ inhibitors. Instead, the selectivity of the compounds for inhibition of PI3Kδ relative to other PI3K isoforms appears to be due primarily to the strong interactions these inhibitors are able to make with Trp760 in the PI3Kδ binding pocket. The pharmacokinetic properties and the ability of compound 5 to inhibit the function of B-cells in vivo are described.
